🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07700472
Starting soon Not applicable

Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma

NCT07700472 · tracked via the Priya Life Science China tracker
Sponsor
Chongqing Medical University
Phase
Not applicable
Started
2026-07-15
Last updated
2026-07-14

Condition(s) studied

Primary AldosteronismAldosterone-Producing Adenoma

Investigational drug(s) / intervention(s)

Endoscopic Ultrasound-Guided Ethanol Ablation

Endoscopic Ultrasound-Guided Ethanol Ablation: Participants with left-sided aldosterone-producing adenoma undergo endoscopic ultrasound-guided ethanol ablation under real-time endoscopic ultrasound guidance.

Study summary

This is a prospective, single-center, single-arm study evaluating endoscopic ultrasound-guided ethanol ablation for left-sided aldosterone-producing adenoma. Eligible participants will receive the ablation procedure and be followed for safety, imaging response, biochemical remission, and clinical remission. The study is expected to enroll 30 participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of left-sided aldosterone-producing adrenal adenoma. 2. Unwillingness to undergo adrenalectomy or presence of contraindications to surgery. 3. Ability and willingness to provide written informed consent. Exclusion Criteria: 1. History of alcohol allergy. 2. Inability to discontinue beta-blockers. 3. Inability to discontinue anticoagulants, antiplatelet agents, or glucocorticoids. 4. Platelet count \<50 × 10\^9/L or uncorrectable coagulation dysfunction. 5. Imaging findings suggestive of adrenal cyst, adrenal hematoma, or myelolipoma. 6. Presence of other active malignancies. 7. Pregnancy or breastfeeding; alcohol abuse; drug abuse; or mental disorder that may interfere with study participation. 8. Severe comorbid conditions, including any of the following: New York Heart Association (NYHA) class III-IV heart failure or hospitalization for worsening chronic heart failure within the previous 3 months; stroke or acute coronary syndrome within the previous 3 months; severe anemia (hemoglobin \<60 g/L); severe hepatic disease (alanine aminotransferase ≥3 × the upper limit of normal); severe renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m²; systemic inflammatory response syndrome (SIRS); poorly controlled diabetes mellitus (fasting blood glucose ≥13.3 mmol/L); severe obesity (body mass index ≥35 kg/m²); untreated aneurysm; or any other severe medical condition that may interfere with treatment or study follow-up. 9. Poor compliance or any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Choongqing

More Chongqing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07700472 on ClinicalTrials.gov ↗ ← All trials in China